AOD 9604 is a fragment of human growth hormone studied for its effect on fat metabolism, with a real but modest evidence base and an important regulatory caveat: it is not an FDA-approved weight loss drug
A., Raguraman, P., Rahimizadeh, K
S., Gayathri, S., Anjitha, N., Athira, K
2-oxobutyrate, a byproduct of the conversion of cystathionine into cysteine and first intermediate in threonine degradation, was also increased with drug treatment
These mechanisms are thought to mitigate T-cell loss and senescence, thereby supporting more robust immune reconstitution once viral suppression is achieved
A European cohort from Erasmus MC (Netherlands) showed that overweight, diabetes, hypertension, and dyslipidemia independently increased liver-related events, including HCC, transplantation, and mortality, with multiple comorbidities amplifying risk several-fold across subgroups, including virally suppressed and non-cirrhotic patients (94)